Table 3.
Study Case # | IL-2 Dose Level | GVHD after DLI |
Study Toxicity* | Remission after DLI | Remission Duration after DLI (Months) | |
---|---|---|---|---|---|---|
Acute | Chronic | |||||
Acute myeloid leukemia | ||||||
2 | I | 0 | NA | N | N | – |
3 | I | III | Extensive | N | Y | 33 |
5 | I | III | Extensive | N | Y† | 35 |
17 | I | 0 | Extensive | N | N | – |
7 | Ia | 0 | NA | N | N | – |
8 | Ia | 0 | 0 | N | N | – |
10 | Ia | II | Extensive | N | Y† | 9 |
11 | Ia | 0 | Extensive | N | Y† | 5 |
12 | Ia | IV | Extensive | Y (GVHD) | Y† | 47 |
14 | Ia | 0 | 0 | N | Y† | 6 |
15 | Ia | 0 | 0 | N | Y | 3 |
Acute lymphoblastic leukemia | ||||||
1 | I | 0 | 0 | N | N | – |
4 | I | III | Extensive | Y (GVHD) | Y† | 8 |
16 | I | 0 | 0 | N | Y† | 5 |
9 | Ia | 0 | Limited | N | N | – |
13 | Ia | III | Extensive | Y (IL2) | Y† | 12 |
6 | II | 0 | NA | Y (IL-2) | N | – |
GVHD indicates graft-versus-host disease; DLI, donor lymphocyte infusion; N, no; Y, yes; NA, not assessable.
Death related to acute or chronic GVHD, development of acute or chronic GVHD with inability to decrease the dose of prednisone to less than 1mg/kg/day within 1 month after initiating treatment for GVHD, or life threatening or fatal organ toxicity attributable to IL-2.
Also remission before DLI following chemotherapy.